Found: 83
Select item for more details and to access through your institution.
Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis.
- Published in:
- Frontiers in Neurology, 2024, p. 1, doi. 10.3389/fneur.2024.1473284
- By:
- Publication type:
- Article
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab.
- Published in:
- BioDrugs, 2024, v. 38, n. 6, p. 755, doi. 10.1007/s40259-024-00671-4
- By:
- Publication type:
- Article
HINT1 peptide/Hsp70 complex induces NK-cell-dependent immunoregulation in a model of autoimmune demyelination.
- Published in:
- European Journal of Immunology, 2014, v. 44, n. 10, p. 3026, doi. 10.1002/eji.201444694
- By:
- Publication type:
- Article
The Heat Shock Protein HSP70 Promotes Th17 Genes' Expression via Specific Regulation of microRNA.
- Published in:
- International Journal of Molecular Sciences, 2020, v. 21, n. 8, p. 2823, doi. 10.3390/ijms21082823
- By:
- Publication type:
- Article
Tumor Necrosis Factor Mediates Myelin Damage in Organotypic Cultures of Nervous Tissuea.
- Published in:
- Annals of the New York Academy of Sciences, 1988, v. 540, n. 1, p. 568, doi. 10.1111/j.1749-6632.1988.tb27175.x
- By:
- Publication type:
- Article
TRAIL‐induced death of human adult oligodendrocytes is mediated by JNK pathway.
- Published in:
- Glia, 2006, v. 53, n. 2, p. 158, doi. 10.1002/glia.20249
- By:
- Publication type:
- Article
Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies.
- Published in:
- Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2023, v. 9, n. 1, p. 1, doi. 10.1177/20552173221142741
- By:
- Publication type:
- Article
Long-term efficacy and safety of three times weekly dosing regimen of glatiramer acetate in relapsing multiple sclerosis patients: Seven-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study.
- Published in:
- Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2021, p. 1, doi. 10.1177/20552173211061550
- By:
- Publication type:
- Article
Long-term efficacy and safety of three times weekly dosing regimen of glatiramer acetate in relapsing multiple sclerosis patients: Seven-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study.
- Published in:
- Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2021, v. 7, n. 4, p. 1, doi. 10.1177/20552173211061550
- By:
- Publication type:
- Article
No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-la.
- Published in:
- Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2018, v. 4, n. 2, p. 1, doi. 10.1177/2055217318760642
- By:
- Publication type:
- Article
No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.
- Published in:
- Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2018, v. 4, n. 1, p. 1, doi. 10.1177/2055217318760642
- By:
- Publication type:
- Article
Hyperintense basal ganglia on T1-weighted magnetic resonance images in a patient with common variable immunodeficiency associated with elevated serum manganese.
- Published in:
- 2002
- By:
- Publication type:
- journal article
Impact of Diminished Expression of circRNA on Multiple Sclerosis Pathomechanisms.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.875994
- By:
- Publication type:
- Article
Heat shock protein 70 associations with myelin basic protein and proteolipid protein in multiple sclerosis brains.
- Published in:
- International Immunology, 2003, v. 15, n. 2, p. 241, doi. 10.1093/intimm/dxg022
- By:
- Publication type:
- Article
Intrathecal administration of mesenchymal stem cells in patients with adrenomyeloneuropathy.
- Published in:
- Frontiers in Neurology, 2024, p. 1, doi. 10.3389/fneur.2024.1345503
- By:
- Publication type:
- Article
Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 14, p. 2177, doi. 10.1177/13524585221116269
- By:
- Publication type:
- Article
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 12, p. 1944, doi. 10.1177/13524585221102584
- By:
- Publication type:
- Article
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 3, p. 429, doi. 10.1177/13524585211024997
- By:
- Publication type:
- Article
Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 1, p. 132, doi. 10.1177/13524585211005339
- By:
- Publication type:
- Article
Hemophagocytic lymphohistiocytosis associated with ocrelizumab treatment in a patient with multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2021, v. 27, n. 11, p. 1803, doi. 10.1177/1352458521993070
- By:
- Publication type:
- Article
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
- Published in:
- Multiple Sclerosis Journal, 2020, v. 26, n. 1, p. 48, doi. 10.1177/1352458518816612
- By:
- Publication type:
- Article
Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.
- Published in:
- Multiple Sclerosis Journal, 2019, v. 25, n. 12, p. 1605, doi. 10.1177/1352458518796675
- By:
- Publication type:
- Article
Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
- Published in:
- Multiple Sclerosis Journal, 2019, v. 25, n. 9, p. 1255, doi. 10.1177/1352458518789884
- By:
- Publication type:
- Article
Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE.
- Published in:
- Multiple Sclerosis Journal, 2018, v. 24, n. 14, p. 1883, doi. 10.1177/1352458517735190
- By:
- Publication type:
- Article
Multiple sclerosis: Serum-derived exosomes express myelin proteins.
- Published in:
- Multiple Sclerosis Journal, 2018, v. 24, n. 4, p. 449, doi. 10.1177/1352458517696597
- By:
- Publication type:
- Article
New insights into the burden and costs of multiple sclerosis in Europe: Results for Poland.
- Published in:
- Multiple Sclerosis Journal, 2017, v. 23, p. 130, doi. 10.1177/1352458517708666
- By:
- Publication type:
- Article
Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing–remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.
- Published in:
- Multiple Sclerosis Journal, 2017, v. 23, n. 6, p. 818, doi. 10.1177/1352458516664033
- By:
- Publication type:
- Article
Insights into multiple sclerosis provided by non-coding RNAs: meeting summary from the symposium ‘Non-coding RNAs in autoimmune disorders of the central nervous system’ on 5 April 2013 in Warsaw, Poland.
- Published in:
- Multiple Sclerosis Journal, 2014, v. 20, n. 11, p. 1439, doi. 10.1177/1352458514521518
- By:
- Publication type:
- Article
Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: The DEFINE study.
- Published in:
- Multiple Sclerosis Journal, 2014, v. 20, n. 2, p. 243, doi. 10.1177/1352458513507817
- By:
- Publication type:
- Article
Multiple sclerosis: Presence of serum antibodies to lipids and predominance of cholesterol recognition.
- Published in:
- Journal of Neuroscience Research, 2017, v. 95, n. 10, p. 1984, doi. 10.1002/jnr.24062
- By:
- Publication type:
- Article
Transcriptional profiling of microdissected areas of active multiple sclerosis lesions reveals activation of heat shock protein genes.
- Published in:
- Journal of Neuroscience Research, 2012, v. 90, n. 10, p. 1941, doi. 10.1002/jnr.23079
- By:
- Publication type:
- Article
Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Optical coherence tomography in multiple sclerosis.
- Published in:
- Journal of Neurology, 2008, v. 255, n. 10, p. 1555, doi. 10.1007/s00415-008-0985-5
- By:
- Publication type:
- Article
Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b.
- Published in:
- Journal of Neurology, 2008, v. 255, n. 4, p. 480, doi. 10.1007/s00415-007-0733-2
- By:
- Publication type:
- Article
CXC Chemokine Receptors Expression during Chronic Relapsing Experimental Autoimmune Encephalomyelitis.
- Published in:
- Annals of the New York Academy of Sciences, 2000, v. 917, n. 1, p. 135, doi. 10.1111/j.1749-6632.2000.tb05377.x
- By:
- Publication type:
- Article
Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial.
- Published in:
- JAMA Neurology, 2023, v. 80, n. 3, p. 298, doi. 10.1001/jamaneurol.2022.5007
- By:
- Publication type:
- Article
Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis.
- Published in:
- JAMA Neurology, 2016, v. 73, n. 9, p. 1089, doi. 10.1001/jamaneurol.2016.1451
- By:
- Publication type:
- Article
Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis.
- Published in:
- JAMA Neurology, 2015, v. 72, n. 12, p. 1433, doi. 10.1001/jamaneurol.2015.2154
- By:
- Publication type:
- Article
Transdermal Application of Myelin Peptides in Multiple Sclerosis Treatment.
- Published in:
- JAMA Neurology, 2013, v. 70, n. 9, p. 1105, doi. 10.1001/jamaneurol.2013.3022
- By:
- Publication type:
- Article
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
- Published in:
- Brain: A Journal of Neurology, 2010, v. 133, n. 8, p. 2232, doi. 10.1093/brain/awq176
- By:
- Publication type:
- Article
Tumour necrosis factor-induced death of adult human oligodendrocytes is mediated by apoptosis inducing factor.
- Published in:
- Brain: A Journal of Neurology, 2005, v. 128, n. 11, p. 2675, doi. 10.1093/brain/awh627
- By:
- Publication type:
- Article
TNF-induced death of adult human oligodendrocytes is mediated by c-jun NH2-terminal kinase-3.
- Published in:
- 2003
- By:
- Publication type:
- journal article
cDNA microarray analysis in multiple sclerosis lesions: detection of genes associated with disease activity.
- Published in:
- Brain: A Journal of Neurology, 2003, v. 126, n. 5, p. 1048, doi. 10.1093/brain/awg107
- By:
- Publication type:
- Article
TRAIL induces death of human oligodendrocytes isolated from adult brain.
- Published in:
- Brain: A Journal of Neurology, 2002, v. 125, n. 11, p. 2469, doi. 10.1093/brain/awf254
- By:
- Publication type:
- Article
Optical coherence tomography assessment of axonal and neuronal damage of the retina in patients with familial and sporadic multiple sclerosis.
- Published in:
- Frontiers in Neurology, 2022, v. 13, p. 1, doi. 10.3389/fneur.2022.953188
- By:
- Publication type:
- Article
Global exosome transcriptome profiling reveals biomarkers for multiple sclerosis.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.
- Published in:
- Annals of Neurology, 2013, v. 73, n. 6, p. 705, doi. 10.1002/ana.23938
- By:
- Publication type:
- Article
Immune regulation of multiple sclerosis by transdermally applied myelin peptides.
- Published in:
- Annals of Neurology, 2010, v. 68, n. 5, p. 593, doi. 10.1002/ana.22219
- By:
- Publication type:
- Article
Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis.
- Published in:
- Annals of Neurology, 2008, v. 63, n. 5, p. 611, doi. 10.1002/ana.21370
- By:
- Publication type:
- Article